Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
HERCULES
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
- NCT04224740 ↗
- Completed
- Latin American Cooperative Oncology Group
- Focused
We haven't built an HCP commentary report on HERCULES (first-line advanced penile cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HERCULES so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Penile Carcinoma
- Interventions
- Pembrolizumab; Standard of care therapy
- Arms
- Pembrolizumab plus standard of care chemotherapy · Experimental
- Enrollment
- 37
- Primary outcomes
- Overall response rate (ORR)
- Sponsor
- Latin American Cooperative Oncology Group with Merck Sharp & Dohme LLC
- Start
- Jun 15, 2020
- Primary completion
- Nov 13, 2023
- Results posted
- No
- Registry record
- NCT04224740 · updated Mar 13, 2024
Publications
linked from the registry- Cotait Maluf F, Trindade K, Preto D, de Almeida Luz M, Medeiros Milhomem Beato P, Assed Bastos D, Holanda Soares JP, Marcondes Lopes V, Werneck de Carvalho LE, Queiroz Borges Muniz D, Racy DJ, de Jesus RG, Rebelatto TF, Werutsky G, Halabi S, Sabino Marques Monteiro F, Poisl Fay A. Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial. JAMA Oncol. 2025 Nov 1;11(11):1314-1320. doi: 10.1001/jamaoncol.2025.3266. PubMed 40965911